Table 1.
Clinical characteristics of the 154 enrolled patients
| Characteristic | Total (n = 154) n (%) |
Primary
non-metastatic (n = 55) n (%) |
De-novo metastatic (n = 49) n (%) |
Recurrent
without RNI history (n = 35) n (%) |
Recurrent
with RNI history (n = 15) n (%) |
|---|---|---|---|---|---|
| Age | |||||
| ≤40 | 26 (16.9%) | 9 (16.4%) | 11 (22.4%) | 3 (8.6%) | 3 (20.0%) |
| >40 | 128 (83.1%) | 46 (83.6%) | 38 (77.6%) | 32 (91.4%) | 12 (80.0%) |
| Tumor laterality | |||||
| Left | 78 (50.7%) | 32 (58.2%) | 23 (46.9%) | 18 (51.4%) | 5 (33.3%) |
| Right | 76 (49.4%) | 23 (41.8%) | 26 (53.1%) | 17 (48.6%) | 10 (66.7%) |
| Histopathological type | |||||
| IDC | 138 (89.6%) | 51 (92.7%) | 47 (95.9%) | 27 (77.1%) | 13 (86.7%) |
| DCIS | 3 (2.0%) | 2 (3.6%) | 1 (2.0%) | 0 (0%) | 0 (0%) |
| ILC | 3 (2.0%) | 1 (1.8%) | 1 (2.0%) | 1 (2.9%) | 0 (0%) |
| Others | 10 (6.5%) | 1 (1.8%) | 0 (0%) | 7 (20.0%) | 2 (13.3%) |
| Breast surgery | |||||
| Breast-conserving surgery | 6 (3.9%) | 1 (1.8%) | 4 (8.2%) | 1 (2.9%) | 0 (0%) |
| Mastectomy | 46 (29.9%) | 2 (3.6%) | 0 (0%) | 30 (85.7%) | 14 (93.3%) |
| Reconstruction | 6 (3.9%) | 1 (1.8%) | 0 (0%) | 4 (11.4%) | 1 (6.7%) |
| No surgery | 96 (62.3%) | 51 (92.7%) | 45 (91.8%) | 0 (0%) | 0 (0%) |
| Axillary surgery | |||||
| ALND | 50 (32.5%) | 0 (0%) | 3 (6.1%) | 35 (100%) | 15 (100%) |
| SLN biopsy only | 7 (4.6%) | 4 (7.3%) | 0 (0%) | 0 (0%) | 0 (0%) |
| No surgery | 97 (63.0%) | 51 (92.7%) | 46 (93.9%) | 0 (0%) | 0 (0%) |
| Molecular type | |||||
| Luminal A | 25 (16.2%) | 10 (18.2%) | 7 (14.3%) | 4 (11.4%) | 4 (26.7%) |
| Luminal B | 56 (36.4%) | 21 (38.2%) | 18 (36.7%) | 11 (31.4%) | 6 (40.0%) |
| Her2-enriched | 26 (16.9%) | 10 (18.2%) | 8 (16.3%) | 6 (17.1%) | 2 (13.3%) |
| Triple-negative | 38 (24.7%) | 13 (23.6%) | 15 (30.6%) | 9 (25.7%) | 1 (6.7%) |
| Unknown | 9 (5.8%) | 1 (1.8%) | 1 (2.0%) | 5 (14.3%) | 2 (13.3%) |
| T stage | |||||
| T0 | 1 (0.7%) | 1 (1.8%) | 0 (0%) | 0 (0%) | 0 (0%) |
| T1 | 18 (11.7%) | 8 (14.5%) | 3 (6.1%) | 6 (17.1%) | 1 (6.7%) |
| T2 | 85 (55.2%) | 31 (56.4%) | 27 (55.1%) | 18 (51.4%) | 9 (60.0%) |
| T3 | 11 (7.1%) | 4 (7.3%) | 7 (14.3%) | 0 (0%) | 0 (0%) |
| T4 | 24 (15.6%) | 10 (18.2%) | 11 (22.4%) | 2 (5.7%) | 1 (6.7%) |
| Tx | 15 (9.7%) | 1 (1.8%) | 1 (2.0%) | 9 (25.7%) | 4 (26.7%) |
| N stage | |||||
| N1 | 25 (16.2%) | 12 (21.8%) | 8 (16.3%) | 4 (11.4%) | 1 (6.7%) |
| N2 | 43 (27.9%) | 18 (32.7%) | 14 (28.6%) | 8 (22.9%) | 3 (20.0%) |
| N3 | 86 (55.8%) | 25 (45.5%) | 27 (55.1%) | 23 (65.7%) | 11 (73.3%) |
| M stage | |||||
| M0 | 69 (44.8%) | 55 (100%) | 0 (0%) | 12 (34.3%) | 2 (13.3%) |
| M1 | 85 (55.2%) | 0 (0%) | 49 (100%) | 23 (65.7%) | 13 (86.7%) |
ALND, axillary lymph node dissection; DCIS, ductal carcinoma in situ; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; RNI, regional nodal irradiation; SLN, sentinal lymph node.